HomeACC 2022Pharmacology

Pharmacology

ACC 2022 | ADAPT-TAVR: Endoxaban Is Not Superior to DAPT After TAVR

DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent...

ACC 2022 | BENTRACIMAB

This study was presented in phase 2, in a healthy population between 50 and 80 years of...

ACC 2022 | PACMAN AMI

Atherosclerosis plaque causing AMI is often large in volume, high in lipids and have a thin fibrous...

ACC 2022 – EDIT-CMD

Roughly 40% of patients receiving a coronary angiography for stable angina (angina episodes twice a week despite...

ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy

Roughly 50% of hypertrophic cardiomyopathies (HCM) are obstructive, and of this percentage, most of symptoms can be...

ACC 2022 – POISE-3: Tranexamic Acid, Bleeding and Cardiovascular Events in Non-Cardiac Surgeries

Tranexamic Acid is an antifibrinolytic which has been shown to reduce bleeding in orthopedic patients and cardiac...